Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.

Korsatko S, Jensen L, Brunner M, Sach-Friedl S, Tarp MD, Holst AG, Heller SR, Pieber TR

Diabetes, obesity & metabolism16 Jul 2018Cited by 25 (Europe PMC)

PMID29893488PMCIDPMC6221089DOI10.1111/dom.13422PepBankPUB-29893488

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the glucagon response to hypoglycaemia was similar with semaglutide and placebo.
In plain wordsIn adults with type 2 diabetes, semaglutide did not change the glucagon response to low blood sugar compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeGlucagon change during hypoglycaemic clamp
Study
n = 35
Comparator
Placebo
Analysis
Primary
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Absolute change in glucagon
88.3 pg/mL
semaglutide
Absolute change in glucagon
83.1 pg/mL
placebo
Estimated difference
5.2 pg/mL
semaglutide minus placebo
Source sentences
Summary
During the hypoglycaemic clamp from 5.5 mmol/L PG to nadir, the absolute change in mean glucagon concentration was similar for semaglutide vs placebo: 88.3 vs 83.1 pg/mL (estimated difference 5.2 pg/mL [95% confidence interval -7.7 to 18.1]).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348801
02HumanRandomized controlled trialEfficacy outcome
Noradrenaline rose less during hypoglycaemia with semaglutide than with placebo.
In plain wordsNoradrenaline rose less during low blood sugar with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseNoradrenaline increase during hypoglycaemia
Study
n = 35
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Concentrations of other counterregulatory hormones increased with both treatments, with a statistically significantly lower increase for noradrenaline and cortisol with semaglutide vs placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348802
03HumanRandomized controlled trialEfficacy outcome
Cortisol rose less during hypoglycaemia with semaglutide than with placebo.
In plain wordsCortisol rose less during low blood sugar with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseCortisol increase during hypoglycaemia
Study
n = 35
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Concentrations of other counterregulatory hormones increased with both treatments, with a statistically significantly lower increase for noradrenaline and cortisol with semaglutide vs placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348803
04HumanRandomized controlled trialEfficacy outcome
The glucose infusion rate needed to hold clamp levels was similar with semaglutide and placebo.
In plain wordsThe glucose needed to keep blood sugar steady in the test was similar with semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeGlucose infusion rate during clamp
Study
n = 35
Comparator
Placebo
Outcome group
Hormone levels · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
The glucose infusion rate to maintain constant clamp levels was similar for each treatment group, suggesting an overall similar counterregulatory response.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348804
05HumanRandomized controlled trialEfficacy outcome
The mean hypoglycaemic symptom score at nadir was lower with semaglutide than with placebo.
In plain wordsPeople felt fewer symptoms of low blood sugar with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseHypoglycaemic symptom score at nadir
Study
n = 35
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
The mean hypoglycaemic symptom score and proportion of participants recognizing hypoglycaemia during the study were lower for semaglutide vs placebo treatment at nadir, but cognitive function test results were similar.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348805
06HumanRandomized controlled trialEfficacy outcome
The proportion of participants recognizing hypoglycaemia at nadir was lower with semaglutide than with placebo.
In plain wordsFewer people noticed low blood sugar with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseProportion recognizing hypoglycaemia at nadir
Study
n = 35
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
The mean hypoglycaemic symptom score and proportion of participants recognizing hypoglycaemia during the study were lower for semaglutide vs placebo treatment at nadir, but cognitive function test results were similar.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348806
07HumanRandomized controlled trialEfficacy outcome
Cognitive function test results were similar with semaglutide and placebo.
In plain wordsThinking test results were similar with semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeCognitive function during hypoglycaemia
Study
n = 35
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
cognitive function test results were similar
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348807
08HumanRandomized controlled trialSafety outcome
No new safety issues were observed for semaglutide.
In plain wordsNo new safety problems were seen with semaglutide.
Peptide
Semaglutide
Outcome
Not applicableSafety of semaglutide
Study
n = 35
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
No new safety issues were observed for semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, placebo-controlled, single-centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.
Report a problemFND-2989348808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02147431

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3821 May 2014 to 20 May 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 13 Aug 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.